In September 2023, the FDA approved the subcutaneous (SC) administration of Entyvio® for the maintenance treatment of adults with moderately to severely active ulcerative colitis (UC). On April 18, 2024, the FDA expanded the approval of Takeda’s Entyvio® (vedolizumab) to include SC administration for the maintenance treatment of adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) Entyvio®. Although the SC injection offers additional options to Entyvio® patients, it does require IV loading doses for two weeks and every two weeks thereafter versus the IV injection of every eight weeks. Currently, Entyvio® SC is not preferred on ProAct’s formulary and may cost plan sponsors more than the Entyvio® IV product.
